細胞バンク(東北大学・加藤研究室)



Cell nameParental cellsTargeted genesGenom editingDeficient
PDIS-1 HEK-293T hsMgat1/GnT-1 TALEN N-glycan
PDIS-2 HEK-293T PDPN CRISPR/Cas9 PDPN
PDIS-4 COS-7 PDPN CRISPR/Cas9 PDPN
PDIS-5 CHO-S FUT8 CRISPR/Cas9 core-fucose
PDIS-6 LN319 podoplanin/PDPN CRISPR/Cas9 podoplanin/PDPN
PDIS-7 U87 MG podoplanin/PDPN CRISPR/Cas9 podoplanin/PDPN
PDIS-9 CHO-S hsMgat1/GnT-1 TALEN N-glycan
PDIS-12 HEK-293T hsMgat1/GnT-1 TALEN N-glycan
PDIS-13 HEK-293T podocalyxin/PODXL CRISPR/Cas9 podocalyxin/PODXL
PDIS-14 CHO-S SLC35A1 CRISPR/Cas9 sialic acid
PDIS-18 HEK-293T SLC35A2 CRISPR/Cas9 galacose
PDIS-20 HEK-293T GnT-1/SLC35A1/SLC35A2 TALEN and CRISPR/Cas9 N-glycan/sialic acid/galacose (triple-knockout)
PDIS-22 HEK-293T SLC35A1 CRISPR/Cas9 sialic acid

*すでに30種類以上樹立しておりますが、論文を発表したものに限り分譲をしております。次々に発表していきますので、随時ご確認ください。
本セルバンクは、AMED創薬等支援技術基盤プラットフォームおよびAMED創薬ライフサイエンス研究支援基盤事業の成果です。上記の細胞は、簡単なMTA(AMED謝辞記載、再分譲不可、販売不可、など)を交わすことで供与可能です。

担当者連絡先:東北大学抗体創薬研究分野 加藤 幸成
E-mail:yukinarikato@gmail.com
抗体バンクもご覧下さい。

参考文献

  • PDIS-1
    1. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med., 6(2); 382-396, 2017
  • PDIS-2
    1. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med., 6(2); 382-396, 2017
    2. Fujii Y, Matsunaga Y, Arimori T, Kitago Y, Ogasawara S, Kaneko MK, Kato Y, Takagi J. Tailored placement of a turn-forming PA tag into the structured domain of a protein to probe its conformational state. J Cell Sci, 29, 1512-1522, 2016
    3. Ogasawara S, Kaneko MK, Kato Y. LpMab-19 Recognizes Sialylated O-glycan on Thr76 of Human Podoplanin. Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/ mab.2016.0031., 2016
    4. Ogasawara S, Kaneko MK, Honma R, Oki H, Fujii Y, Takagi M, Suzuki H, Kato Y.* Establishment of Mouse Monoclonal Antibody LpMab-13 against Human Podoplanin. Monoclon. Antib. Immunodiagn. Immunother., 35(3):155-162, 2016
    5. Kato Y*, Ogasawara Y, Oki H, Honma R, Takagi M, Fujii Y, Nakamura T, Saidoh N, Kanno H, Umetsu M, Kamata S, Kubo H, Yamada M, Sawa Y, Morita K, Harada H, Suzuki H, Kaneko MK. Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin. Monoclon. Antib. Immunodiagn. Immunother., 35(2), 109-116, 2016
    6. Kato Y, Ogasawara S, Oki H, Goichberg P, Honma R, Fujii Y, Kaneko MK. LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-glycan on Thr52 of Platelet Aggregation-stimulating Domain of Human Podoplanin. PLoS One, 11(3), e0152912, 2016
  • PDIS-4
    1. Kato Y, Ogasawara S, Oki H, Goichberg P, Honma R, Fujii Y, Kaneko MK. LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-glycan on Thr52 of Platelet Aggregation-stimulating Domain of Human Podoplanin. PLoS One, 11(3), e0152912, 2016
  • PDIS-5
    1. Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y*. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med.,,6(4): 768-777, 2017 (PDF)
  • PDIS-6
    1. Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y*. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med., ,6(4): 768-777, 2017 (PDF)
    2. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med., 6(2); 382-396, 2017
    3. Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, Kato Y, Chandramohan V, Bigner DD, Natsume A.. CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains. Cancer Immunol Res.;4(3):259-68.,2016 (PDF)
    4. Ogasawara S, Kaneko MK, Kato Y. LpMab-19 Recognizes Sialylated O-glycan on Thr76 of Human Podoplanin. Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/ mab.2016.0031., 2016
    5. Ogasawara S, Oki H, Kaneko MK, Hozumi Y, Liu X, Honma R, Fujii Y, Nakamura T, Goto K, Takagi M, Kato Y*. Development of a monoclonal antibody LpMab-10 recognizing non-glycosylated PLAG1/2 domain including Thr34 of human podoplanin. Monoclon. Antib. Immunodiagn. Immunother., 34(5), 318-326, 2015
    6. Kaneko MK, Oki H, Hozumi Y, Liu X, Ogasawara S, Takagi M, Goto K, Kato Y* A monoclonal antibody LpMab-9 recognizes O-glycosylated N-terminus of human podoplanin. Monoclon. Antib. Immunodiagn. Immunother., 34(5), 310-317, 2015
    7. Kato Y, Ogasawara S, Oki H, Goichberg P, Honma R, Fujii Y, Kaneko MK. LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-glycan on Thr52 of Platelet Aggregation-stimulating Domain of Human Podoplanin. PLoS One, 11(3), e0152912, 2016
  • PDIS-7
    1. Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, Kato Y, Chandramohan V, Bigner DD, Natsume A.. CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains. Cancer Immunol Res.;4(3):259-68.,2016 (PDF)
  • PDIS-9
    1. Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y*. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med., ,6(4): 768-777, 2017 (PDF)
    2. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med., 6(2); 382-396, 2017
  • PDIS-12
    1. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med., 6(2); 382-396, 2017
  • PDIS-13
    1. Ogasawara S, Kaneko MK, Yamada S, Honma R, Nakamura T, Saidoh N, Yanaka M, Yoshida K, Fujii Y, Kato Y.* PcMab-47: Novel Anti-human Podocalyxin Monoclonal Antibody for Immunohistochemistry. Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/mab.2017.0008, in press
  • PDIS-14
    1. Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y*. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med., ,6(4): 768-777, 2017 (PDF)
    2. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med., 6(2); 382-396, 2017
  • PDIS-18
    1. Ogasawara S, Kaneko MK, Yamada S, Honma R, Nakamura T, Saidoh N, Yanaka M, Yoshida K, Fujii Y, Kato Y.* PcMab-47: Novel Anti-human Podocalyxin Monoclonal Antibody for Immunohistochemistry. Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/mab.2017.0008, in press
  • PDIS-20
    1. Ogasawara S, Kaneko MK, Yamada S, Honma R, Nakamura T, Saidoh N, Yanaka M, Yoshida K, Fujii Y, Kato Y.* PcMab-47: Novel Anti-human Podocalyxin Monoclonal Antibody for Immunohistochemistry. Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/mab.2017.0008, in press
  • PDIS-22
    1. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med., 6(2); 382-396, 2017
    2. Ogasawara S, Kaneko MK, Yamada S, Honma R, Nakamura T, Saidoh N, Yanaka M, Yoshida K, Fujii Y, Kato Y.* PcMab-47: Novel Anti-human Podocalyxin Monoclonal Antibody for Immunohistochemistry. Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/mab.2017.0008, in press